Stay updated with breaking news from Nasdaq Dcph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) – Equities research analysts at SVB Leerink cut their Q2 2023 EPS estimates for shares of Deciphera Pharmaceuticals in a research note issued to investors on Wednesday, May 3rd. SVB Leerink analyst A. Berens now forecasts that the company will earn ($0.65) per share for the quarter, down […]
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) had its price objective decreased by Stifel Nicolaus from $17.00 to $14.00 in a research note issued to investors on Thursday, The Fly reports. Several other analysts have also issued reports on DCPH. HC Wainwright restated a buy rating and issued a $25.00 price target on shares of Deciphera […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) – Research analysts at SVB Leerink decreased their FY2025 earnings estimates for shares of Deciphera Pharmaceuticals in a research note issued on Tuesday, April 25th. SVB Leerink analyst A. Berens now forecasts that the company will post earnings per share of $0.26 for the year, down from their […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 3,370,000 shares, a decrease of 40.9% from the March 31st total of 5,700,000 shares. Based on an average daily volume of 745,900 shares, the short-interest ratio is […]
Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) have been assigned an average rating of “Moderate Buy” from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have given a buy recommendation […]